This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.
Patterson Companies-SprintRay Deal to Boost Dental Unit
by Zacks Equity Research
Patterson Companies (PDCO) focuses on acquisitions to boost dental segment.
Why Align Technology (ALGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Align Technology (ALGN) is in a good position to beat earnings at its next report as it has a favorable Zacks Rank and positive Earnings ESP.
CVS Health's Aetna Buyout to Change Healthcare Landscape
by Zacks Equity Research
Once the Aetna deal is through, CVS Health (CVS) expects to draw $750 million from near-term synergies with low to mid-single digit accretion in the second year.
Cooper Companies' (COO) CooperVision Buys Paragon for $80M
by Zacks Equity Research
The Cooper Companies (COO) focuses on strategic acquisitions to drive inorganic growth.
Only 4 Dental Stocks to Buy Amid MedTech Regulatory Woes
by Zacks Equity Research
After a stellar five-year run on the bourse, the performance of the dental industry has taken a hit in the last two years.
Align Technology (ALGN) Grows on InvisAlign System Strength
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: IDEXX Laboratories, Luminex, Masimo, Align Technology and Cooper Companies
Align Teams Up with Exocad to Expand in Digital Scanning
by Zacks Equity Research
Align's (ALGN) collaboration with CAD/CAM software provider, Exocad GmbH, is likely to integrate the Chairside CAD software into Align's iTero Element intraoral scanner.
5 MedTech Stocks to Beat Tax Hazards With Positive Returns
by Zacks Equity Research
Trump's tax reform policies promise to cut corporate taxes. However, the future of the U.S. MedTech industry depends on the much-awaited decision on the 2.3% medical device tax.
Anatomy of Success: Align Technology (ALGN)
by Brian Hamilton
After becoming a Zacks Rank #1, ALGN posted two consecutive record quarters.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
Masimo (MASI) continues to grow on innovation and product launches.
Luminex (LMNX) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Luminex (LMNX) gains from recent FDA approvals and product launches.
What Falling Estimates & Price Mean for Patterson Companies (PDCO)
by Zacks Equity Research
It seems to be a wise decision for investors to drop Patterson Companies (PDCO) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Zimmer Biomet Hurt by Supply Delay, Knee Challenges Remain
by Zacks Equity Research
Zimmer Biomet (ZBH) struggles with supply delay problem related to some of its products, causing inability to win back lost customers and gain new ones.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
Align Technology (ALGN) continues to boost investors' confidence on consistent strength in InvisAlign.
AmerisourceBergen to Take Over H. D. Smith for $815 Million
by Zacks Equity Research
AmerisourceBergen (ABC) strives to strengthen core businesses. The H. D. Smith buyout is likely to strengthen the Pharmaceutical Distribution Segment.
Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind
by Zacks Equity Research
Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.
Medtronic Wins FDA Nod for Azure Pacemakers, Grows in CVG
by Zacks Equity Research
Medtronic (MDT) strives to improve its Cardiac Rhythm and Heart Failure division.
DENTSPLY SIRONA Strong on Deal Renewals, Forex Woes Stay
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) renewed distribution deal will help the company gain market traction. However, forex woes remain a concern.
McKesson Gains From Distribution Business Amid Pricing Woes
by Zacks Equity Research
McKesson Corporation's (MCK) Distribution business is driven by market growth and acquisitions. However, pricing remains a concern.
Haemonetics (HAE) at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Haemonetics (HAE) focuses on development and launch of NexSys PCS plasmapheresis system.
Varian's Halcyon Receives Shonin Approval, Grows in Oncology
by Zacks Equity Research
Varian Medical (VAR) adopts various strategies to boost the Oncology Segment.
5 Stocks with Recent Price Strength to Boost Your Portfolio
by Zacks Equity Research
One should primarily look for stocks that have recently been witnessing price increase. Actually, stocks seeing price strength recently have a high chance of carrying the momentum forward.
AmerisourceBergen's PharMEDium Slows Down, Competition Rife
by Zacks Equity Research
AmerisourceBergen's (ABC) prospects hurt by tepid performance at PharMEDium. Also, steep competition is a cause for concern.
Align Technology-Glidewell Dental Deal to Boost iTero Uptake
by Zacks Equity Research
Align Technology (ALGN) progresses with deals to boost the Scanners and Services segment.